CLINICAL RESEARCH: HEART RHYTHM DISORDER
Obesity Is a Major Determinant of Radiation Dose in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation
Joris Ector, MD*,*,
Octavian Dragusin, MSc ,
Bert Adriaenssens, MD*,
Wim Huybrechts, MD*,
Rik Willems, MD, PhD*,
Hugo Ector, MD, PhD*,2 and
Hein Heidbüchel, MD, PhD*,1,3
* Department of Cardiology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium
Department of Radiology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium.
Manuscript received August 31, 2006;
revised manuscript received March 15, 2007,
accepted March 20, 2007.
* Reprint requests and correspondence: Dr. Joris Ector, Cardiology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. (Email: Joris.Ector{at}uz.kuleuven.ac.be).
Objectives: This study sought to evaluate the impact of obesity on patient radiation dose during atrial fibrillation (AF) ablation procedures under fluoroscopic guidance.
Background: Obesity is a risk factor for AF and its recurrence after ablation. It increases patient radiation dose during fluoroscopic imaging, but this effect has not been quantified for AF ablation procedures.
Methods: Effective radiation dose and lifetime attributable cancer risk were calculated from dose-area product (DAP) measurements in 85 patients undergoing AF ablation guided by biplane low-frequency pulsed fluoroscopy (3 frames/s). Three dose calculation methods were used (Monte Carlo simulation, dose conversion coefficients, and depth-profile dose curves).
Results: Median DAP for all patients was 119.6 Gy·cm2 (range 13.9 to 446.3 Gy·cm2) for procedures with a median duration of 4 h and 83 ± 26 min of fluoroscopy. Body mass index was a more important determinant of DAP than total fluoroscopy time (r = 0.74 vs. 0.37, p < 0.001), with mean DAP values per hour of fluoroscopy of 58 ± 40 Gy·cm2, 110 ± 43 Gy·cm2, and 184 ± 79 Gy·cm2 in normal, overweight, and obese patients, respectively. The corresponding effective radiation doses for AF ablation procedures were 15.2 ± 7.8 mSv, 26.7 ± 11.6 mSv, and 39.0 ± 15.2 mSv, respectively (Monte Carlo). Use of conversion coefficients resulted in higher effective dose estimates than other methods, particularly in obese patients. Mean attributable lifetime risk of all-cancer mortality was 0.060%, 0.100%, and 0.149%, depending on weight class.
Conclusions: Obese patients receive more than twice the effective radiation dose of normal-weight patients during AF ablation procedures. Obesity needs to be considered in the risk-benefit ratio of AF ablation and should prompt further measures to reduce radiation exposure.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | BMI = body mass index | | DAP = dose-area product | | HVL = half-value layer | | LAO = left anterior oblique | | NRPB = National Radiological Protection Board | | PSD = peak skin dose | | PV = pulmonary vein | | PVI = pulmonary vein isolation | | RAO = right anterior oblique |
|
This article has been cited by other articles:

|
 |

|
 |
 
G. Z. Duray and S. H. Hohnloser
Fighting with the invisible: radiation exposure in cardiac resynchronization therapy
Europace,
December 1, 2009;
11(12):
1575 - 1576.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Kim and D. L. Miller
MINIMISING RADIATION EXPOSURE TO PHYSICIANS PERFORMING FLUOROSCOPICALLY GUIDED CARDIAC CATHETERISATION PROCEDURES: A REVIEW
Radiat Prot Dosimetry,
March 27, 2009;
(2009)
ncp052v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Niinuma, R. T. George, A. Arbab-Zadeh, J. A.C. Lima, and C. A. Henrikson
Imaging of pulmonary veins during catheter ablation for atrial fibrillation: the role of multi-slice computed tomography
Europace,
November 1, 2008;
10(suppl_3):
iii14 - iii21.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-M. Cha, P. A. Friedman, S. J. Asirvatham, W.-K. Shen, T. M. Munger, R. F. Rea, P. A. Brady, A. Jahangir, K. H. Monahan, D. O. Hodge, et al.
Catheter Ablation for Atrial Fibrillation in Patients With Obesity
Circulation,
May 20, 2008;
117(20):
2583 - 2590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
Eur. Heart J.,
November 2, 2007;
28(22):
2803 - 2817.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm, H.-C. Diener, A. Goette, G. Hindricks, S. Hohnloser, L. Kappenberger, et al.
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Europace,
November 1, 2007;
9(11):
1006 - 1023.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|